Biotie will issue 161,448,371 shares to acquire Switzerland-based Synosia.
Nasdaq-listed biotechnology company Biotie Therapies has acquired corporate venturing-backed Synosia for $121m just three months after lining up a potential $725m in royalty payments.
Biotie will issue 161,448,371 shares to acquire Switzerland-based Synosia.
After the merger, Timo Veromaa will continue as executive president of Biotie, while Synosia’s chief executive, Ian Massey, will become chief operating officer and president of US Operations, a new position.
Stephen Bandak, Synosia’s chief medical officer will have the same role for Biotie. Chris Piggott, Biotie’s…
